CASE STUDY: SEQIRUS

by Ian Hughes
3rd March 2021

The world’s no.2 influenza vaccine provider

Seqirus, the world’s no.2 influenza vaccine provider, recently announced a £22.1 million investment for its site in Liverpool.

The company, which is part of global biotherapeutics leader CSL Limited, is developing a new £15.3 million manufacturing facility to support the production of influenza vaccines at its Liverpool site, complemented by a £6.8 million warehouse which opened in early 2017. The development paves the way for the future expansion of product manufacturing at the Liverpool site, which plays an important role in Seqirus’ global operations.

Ian Hughes
Ian Hughes
Marketing Manager
3rd March 2021

Speak to an expert

Alice Lamb
Alice Lamb
Head of Account Management, Investment Services

    For general enquiries contact:
    Alice.Lamb@growthplatform.org

    X